Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation (RAFT-AF)

8 мая 2026 г. обновлено: Ottawa Heart Institute Research Corporation

A Randomized Ablation-based Atrial Fibrillation Rhythm Control Versus Rate Control Trial in Patients With Heart Failure and High Burden Atrial Fibrillation

Atrial fibrillation and heart failure are two common heart conditions that are associated with an increase in death and suffering. When both of these two conditions occur in a patient the patient's prognosis is poor. These patients have poor life quality and are frequently admitted to the hospital. The treatment of atrial fibrillation in heart failure patients is extremely challenging. Two options for managing the atrial fibrillation are permitting the atrial fibrillation to continue but controlling the heart rate, or to convert the atrial fibrillation rhythm back to normal and try to maintain the heart in sinus rhythm. Until now, the method to keep the patient in normal sinus rhythm is with antiarrhythmic drugs. Studies using antiarrhythmic drugs to control the rhythm failed to show any survival benefit when compared with permitting the patient to be in atrial fibrillation. In the last few years, new development in techniques and technologies now enable catheter ablation (cauterization of tissue in the heart with a catheter) to be a successful treatment in abolishing atrial fibrillation and that this approach is better than antiarrhythmic drug to control the rhythm. However, there has not been any long-term study to determine whether catheter ablation to abolish atrial fibrillation in heart failure patients would reduce mortality or admissions for heart failure.

This study is to compare the effect of catheter ablation-based atrial fibrillation rhythm control to rate control in patients with heart failure and high burden atrial fibrillation on the composite endpoint of all-cause mortality and heart failure events defined as an admission to a healthcare facility for > 24 hours or clinically significant worsening heart failure leading to an intervention (defined as treatment in an emergency department, a same-day access clinic, or an infusion centre) or unscheduled visits to a healthcare provider for administration of an intravenous diuretic and an increase in chronic heart failure therapy. This study may have a dramatic impact on the way the investigators manage these patients with atrial fibrillation and heart failure and may improve the outlook and well being of these patients.

Обзор исследования

Подробное описание

Substudy_ In a subset of patients, following informed consent, additional data collection will include annual NT-proBNP/BNP measurements, Echocardiogram baseline and annually and 14 Day ECG Continuous Monitoring at six month intervals.

Updated June 2024:

Additional analysis will be completed using the winratio analysis for the hierarchical primary outcome of:

  1. All-cause mortality (time to event)
  2. Heart Failure Events (number of events per year) defined as an admission to a healthcare facility for > 24 hours or clinically significant worsening heart failure leading to an intervention (defined as treatment in an emergency department, a same-day access clinic, or an infusion centre) or unscheduled visits to a healthcare provider for administration of an intravenous diuretic as accepted by FDA, and an increase in chronic heart failure therapy
  3. Minnesota Living with Heart Failure Questionnaire (change from baseline to 12-month)
  4. Six Minute Hall Walk Test (change from baseline to 12-month)

Тип исследования

Интервенционный

Регистрация (Действительный)

411

Фаза

  • Непригодный

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Бразилия, 90620-001
        • Instituto de Cardiologia-FUC RS
    • Alberta
      • Calgary, Alberta, Канада, T2N 2T9
        • Libin Cardiovascular Institute of Alberta, Calgary
      • Edmonton, Alberta, Канада, T5H 3V9
        • Royal Alexandra Hospital
    • British Columbia
      • Vancouver, British Columbia, Канада, V6Z 1Y6
        • Vancouver General
      • Victoria, British Columbia, Канада, V8R 4R2
        • Royal Jubilee Hospital
    • Nova Scotia
      • Halifax, Nova Scotia, Канада, B3H 3A7
        • Queen Elizabeth II Health Science
    • Ontario
      • Hamilton, Ontario, Канада, L8L 2X2
        • Hamilton Health Sciences Centre
      • Kingston, Ontario, Канада, K7L 2V7
        • Kingston General Hospital
      • Kitchener, Ontario, Канада, N2M 1B2
        • St. Mary's General Hospital
      • London, Ontario, Канада, N6A 5A5
        • London Health Sciences Centre
      • Newmarket, Ontario, Канада, L3Y 8C3
        • Southlake Regional Health Care
      • Ottawa, Ontario, Канада, K1Y 4W7
        • University of Ottawa Heart Institute
      • Toronto, Ontario, Канада, M4N 3M5
        • Sunnybrook Health Sciences Centre
      • Toronto, Ontario, Канада, M5G 2M9
        • Toronto General Hospital, University Health Network
    • Quebec
      • Montreal, Quebec, Канада, H3A 1A1
        • McGill University Health Centre
      • Montreal, Quebec, Канада, H1T 1C8
        • Institute de Cardiologie de Montréal
      • Montreal, Quebec, Канада, H2L 4M1
        • CHUM Centre hospitalier universitaire de Montréal
      • Québec, Quebec, Канада, G1V 4G5
        • Insitut universitaire de cardiologie and pneumologie de Quebec
      • Sherbrooke, Quebec, Канада, J1H 5N4
        • CHUS Centre Hospitalier Universitaire de Sherbrooke
      • Taipei, Тайвань, 100
        • National Taiwan University Hospital
      • Stockholm, Швеция, S-171 76
        • Karolinska University Hospital

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Описание

Inclusion Criteria:

  1. Patients with one of the following AF categories and at least one ECG documentation of AF

    • High burden Paroxysmal defined as ≥ 4 episodes of AF in the last 6 months, and at least one episode > 6 hours (and no episode requiring cardioversion and no episode > 7 days)
    • Persistent AF (1) defined as ≥ 4 episodes of AF in the last 6 months, and at least one episode > 6 hours, and at least one AF episode less than 7 days but requires cardioversion. No AF episodes are > 7 days
    • Persistent AF (2) as defined by at least one episode of AF > 7 days but not > 1 year
    • Long term persistent AF defined as an AF episode, at least one year in length and no episodes > 3 years
  2. Optimal therapy for heart failure of at least 6 weeks (according to 2009 ACCF/AHA class 1 recommendations).
  3. HF with NYHA class II or III symptoms with either impaired LV function (LVEF ≤ 45%) as determined by EF assessment within the previous 12 months or preserved LV function (LVEF > 45%) determined by by EF assessment within the previous 12 months
  4. NT-pro BNP measures:

    A) Patient has been hospitalized for Heart Failure* in the past 9 months, has been discharged AND:

    i- Is presently in Normal Sinus Rhythm and NT-pro BNP is ≥ 400 pg/mL

    ii- Is presently in Atrial Fibrillation and NT-pro BNP is ≥ 600 pg/mL

    OR

    B) Patient has had no hospitalization for Heart Failure in the past 9 months AND:

    i- Has had paroxysmal Atrial Fibrillation, is presently in Normal Sinus Rhythm and NT-proBNP is ≥ 600 pg/mL

    ii- Is presently in Atrial Fibrillation and NT-proBNP is ≥ 900 pg/mL

    *Heart Failure Admission is defined as admission to hospital > 24 hours and received treatment for Heart failure

  5. Suitable candidate for catheter ablation or rate control therapy for the treatment of AF
  6. Age ≥18

Exclusion Criteria:

  1. Have an LA dimension > 55 mm as determined by an echocardiography within the previous year
  2. Had an acute coronary syndrome or coronary artery bypass surgery within 12 weeks
  3. Have rheumatic heart disease, severe aortic or mitral valvular heart disease using the AHA/ACC guidelines
  4. Have congenital heart disease including previous ASD repair, persistent left superior vena cava
  5. Had prior surgical or percutaneous AF ablation procedure or atrioventricular nodal (AVN) ablation
  6. Have a medical condition likely to limit survival to < 1 year
  7. Have New York Heart Association (NYHA) class IV heart failure symptoms
  8. Have contraindication to systematic anticoagulation
  9. Have renal failure requiring dialysis
  10. AF due to reversible cause e.g. hyperthyroid state
  11. Are pregnant
  12. Are included in other clinical trials that will affect the objectives of this study
  13. Have a history of non-compliance to medical therapy
  14. Are unable or unwilling to provide informed consent

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Активный компаратор: Rhythm Control
Patients randomized to catheter ablation-based AF rhythm control group will receive optimal Heart Failure therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug.
Patients randomized to catheter ablation-based AF rhythm control group will receive optimal HF therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug
Другие имена:
  • Катетерная абляция
Активный компаратор: Rate Control
Patients in the rate control group will receive optimal Heart Failure therapy and rate control measures to achieve a resting HR < 80 bpm and 6-minute walk HR < 110 bpm.
Patients in the rate control group will receive optimal HF therapy and rate control measures to achieve a resting HR < 80 bpm and 6-minute walk HR < 110 bpm.
Другие имена:
  • Standard medical therapy

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Composite of All-cause Mortality and Heart Failure Events
Временное ограничение: Baseline to study completion, an average of 24 months
Heart failure event defined as an admission to a healthcare facility for > 24 hours or clinically significant worsening heart failure leading to an intervention (defined as treatment in an emergency department, a same-day access clinic, or an infusion centre) or unscheduled visits to a healthcare provider for administration of an intravenous diuretic as accepted by FDA and an increase in chronic heart failure therapy
Baseline to study completion, an average of 24 months

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
All-cause mortality
Временное ограничение: Baseline to a minimum of 24 months
All-cause mortality
Baseline to a minimum of 24 months
Heart Failure events
Временное ограничение: Baseline to a minimum of 24 months
Heart failure event defined as an admission to a healthcare facility for > 24 hours or clinically significant worsening heart failure leading to an intervention (defined as treatment in an emergency department, a same-day access clinic, or an infusion centre) or unscheduled visits to a healthcare provider for administration of an intravenous diuretic as accepted by FDA and an increase in chronic heart failure therapy
Baseline to a minimum of 24 months
Health related QoL
Временное ограничение: Baseline to a minimum of 24 months
Minnesota Living with Heart Failure. Scoring: The higher the score, the worse the HRQL
Baseline to a minimum of 24 months
Health related QoL
Временное ограничение: Baseline to a minimum of 24 months
EuroQol- 5 Dimension. Scoring 0 = worst to 100 = best
Baseline to a minimum of 24 months
Health related QoL
Временное ограничение: Baseline to a minimum of 24 months
Atrial Fibrillation Effect on Quality-of-life. Scoring 0 = worst to 100 = best
Baseline to a minimum of 24 months
Exercise capacity
Временное ограничение: Baseline to a minimum of 24 months
as determined by 6 Minute Hall walk distance
Baseline to a minimum of 24 months
NT-proBNP/BNP at 1 year and at 2 year follow-up
Временное ограничение: Baseline to a minimum of 24 months
NT-proBNP/BNP
Baseline to a minimum of 24 months
All-cause mortality and heart failure events in patients with HF, impaired (LVEF≤45%) LV function and high burden AF
Временное ограничение: Baseline to a minimum of 24 months
Baseline to a minimum of 24 months
All-cause mortality and heart failure events in patients with HF, preserved (LVEF > 45%) LV function and high burden AF
Временное ограничение: Baseline to a minimum of 24 months
Baseline to a minimum of 24 months
Health economics
Временное ограничение: Baseline to a minimum of 24 months
Cost economics
Baseline to a minimum of 24 months

Другие показатели результатов

Мера результата
Мера Описание
Временное ограничение
LV function and remodeling (LVESVi) at 1 year and 2 year follow-up
Временное ограничение: Baseline to a minimum of 24 months
Echocardiogram measure LVESVi
Baseline to a minimum of 24 months
AF Burden at 1 year and 2 year follow-up
Временное ограничение: Baseline to a minimum of 24 months
14 Day Continuous ECG monitoring
Baseline to a minimum of 24 months
Total number of heart failure events
Временное ограничение: Baseline to a minimum of 24 months
Heart failure event defined as an admission to a healthcare facility for > 24 hours or clinically significant worsening heart failure leading to an intervention (defined as treatment in an emergency department, a same-day access clinic, or an infusion centre) or unscheduled visits to a healthcare provider for administration of an intravenous diuretic as accepted by FDA and an increase in chronic heart failure therapy
Baseline to a minimum of 24 months
Total number of Cardiovascular hospitalizations
Временное ограничение: Baseline to a minimum of 24 months
Cardiovascular hospitalizations
Baseline to a minimum of 24 months
Safety (Adverse Events)
Временное ограничение: Baseline to a minimum of 24 months
Thromboembolic events, symptomatic Pulmonary vein stenosis, atrio-esophageal fistula, pericardial effusion requiring pericardiocentesis, major bleeding requiring blood transfusion, amiodarone induced thyroid, pulmonary and other toxicity
Baseline to a minimum of 24 months

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Следователи

  • Главный следователь: Anthony Tang, MD FRCPC, Western University
  • Главный следователь: George Wells, PhD, Ottawa Heart Institute Research Corporation

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования

1 сентября 2011 г.

Первичное завершение (Действительный)

1 мая 2021 г.

Завершение исследования (Действительный)

1 июня 2021 г.

Даты регистрации исследования

Первый отправленный

17 августа 2011 г.

Впервые представлено, что соответствует критериям контроля качества

18 августа 2011 г.

Первый опубликованный (Оцененный)

19 августа 2011 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

11 мая 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

8 мая 2026 г.

Последняя проверка

1 июля 2024 г.

Дополнительная информация

Термины, связанные с этим исследованием

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться